Analysis of Clinical Characteristics and Risk Factors for Drug Resistance in Newly-Treated Patients with Pulmonary Tuberculosis Complicated with Chronic Obstructive Pulmonary Disease

References

• Sinigaglia A, Peta E, Riccetti S, et al. Tuberculosis-associated microRNAs: from pathogenesis to disease biomarkers. Cells. 2020;9(10):2160. doi:10.3390/cells9102160
   Web of Science ®Google Scholar
• Harding E. WHO global progress report on tuberculosis elimination. Lancet Respir Med. 2020;8(1):19. doi:10.1016/S2213-2600(19)30418-7
   PubMed Web of Science ®Google Scholar
• Zhao JN, Zhang XX, He XC, et al. Multidrug-resistant tuberculosis in patients with chronic obstructive pulmonary disease in China. PLoS One. 2015;10(8):e0135205. doi:10.1371/journal.pone.0135205
   PubMed Web of Science ®Google Scholar
• Lee C-H, Lee M-C, Lin -H-H, et al. Pulmonary tuberculosis and delay in anti-tuberculous treatment are important risk factors for chronic obstructive pulmonary disease. PLoS One. 2012;7:e37978. doi:10.1371/journal.pone.0037978
   PubMed Web of Science ®Google Scholar
• Kim JH, Park JS, Kim KH, et al. Inhaled corticosteroid is associated with an increased risk of TB in patients with COPD. Chest. 2013;143(4):1018–1024. doi:10.1378/chest.12-1225
   PubMed Web of Science ®Google Scholar
• Huang TM, Kuo KC, Wang YH, et al.; On the behalf of Taiwan Clinical Trial Consortium for Respiratory Diseases (TCORE). Risk of active tuberculosis among COPD patients treated with fixed combinations of long-acting beta2 agonists and inhaled corticosteroids. BMC Infect Dis. 2020;20(1):706. doi:10.1186/s12879-020-05440-6
   PubMed Web of Science ®Google Scholar
• Acharya B, Acharya A, Gautam S, et al. Advances in diagnosis of Tuberculosis: an update into molecular diagnosis of Mycobacterium tuberculosis. Mol Biol Rep. 2020;47(5):4065–4075. doi:10.1007/s11033-020-05413-7
   PubMed Web of Science ®Google Scholar
• Li Z, Mao X, Liu Q, et al. Functional variations of the TLR4 gene in association with chronic obstructive pulmonary disease and pulmonary tuberculosis. BMC Pulm Med. 2019;19(1):184. doi:10.1186/s12890-019-0939-y
   Web of Science ®Google Scholar
• Suárez I, Fünger SM, Kröger S, et al. The diagnosis and treatment of tuberculosis. Dtsch Arztebl Int. 2019;116(43):729–735. doi:10.3238/arztebl.2019.0729
   PubMed Web of Science ®Google Scholar
• Mirza S, Clay RD, Koslow MA, et al. COPD guidelines: a review of the 2018 GOLD report. Mayo Clin Proc. 2018;93(10):1488–1502. doi:10.1016/j.mayocp.2018.05.026
   PubMed Web of Science ®Google Scholar
• Sia JK, Rengarajan J. Immunology of Mycobacterium tuberculosisInfections. Microbiol Spectr. 2019;7(4):10.
   Web of Science ®Google Scholar
• Huang YH, Kuang YB, Liang HD, et al. Discussion of the optimum concentration of bacterial liquid in the drug sensitivity test of Mycobacterium tuberculosis. Med Lab Sci Clin. 2018;29(3):21–24.
   Google Scholar
• Gallo JF, Pinhata JMW, Saraceni CP, et al. Evaluation of the BACTEC MGIT 960 system and the resazurin microtiter assay for susceptibility testing of Mycobacterium tuberculosis to second-line drugs. J Microbiol Methods. 2017;139:168–171. doi:10.1016/j.mimet.2017.06.007
   Web of Science ®Google Scholar
• MacNeil A, Glaziou P, Sismanidis C, et al. Global epidemiology of tuberculosis and progress toward meeting global targets - worldwide, 2018. MMWR Morb Mortal Wkly Rep. 2020;69(11):281–285. doi:10.15585/mmwr.mm6911a2
   PubMed Web of Science ®Google Scholar
• Sakornsakolpat P, Prokopenko D, Lamontagne M, et al. Genetic landscape of chronic obstructive pulmonary disease identifies heterogeneous cell-type and phenotype associations. Nat Genet. 2019;51(3):494–505. doi:10.1038/s41588-018-0342-2
   PubMed Web of Science ®Google Scholar
• Perez-Padilla R, Menezes AMB. Chronic obstructive pulmonary disease in Latin America. Ann Glob Health. 2019;85(1):7. doi:10.5334/aogh.2418
   Web of Science ®Google Scholar
• Menezes AM, Hallal PC, Perez-Padilla R, et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in Latin America. Eur Respir J. 2007;30(6):1180–1185. doi:10.1183/09031936.00083507
   PubMed Web of Science ®Google Scholar
• Lam KB, Jiang CQ, Jordan RE, et al. Prior TB, smoking and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study. Chest. 2010;137(3):593–600. doi:10.1378/chest.09-1435
   PubMed Web of Science ®Google Scholar
• Li GJ, Tian XM. Analysis of clinical features and misdiagnosis causes of elderly and middle-aged and young patients with pulmonary tuberculosis. J Ningxia Med Univ. 2020;42(8):830–833.
   Google Scholar
• Zhang ST, Tang BJ, Zhang XW, et al. Clinical analysis of chronic obstructive pulmonary disease with tuberculosis in elderly people. Chin Commun Doctors. 2020;36(12):34.
   Google Scholar
• Park YB, Rhee CK, Yoon HK, et al.; Committee of the Korean COPD Guideline 2018. Revised (2018) COPD Clinical PracticeGuideline of the Korean Academy of Tuberculosis and Respiratory Disease: a Summary. Tuberc Respir Dis. 2018;81(4):261–273. doi:10.4046/trd.2018.0029
   Web of Science ®Google Scholar
• Park HY, Kang D, Shin SH, et al. Pulmonary tuberculosis and the incidence of lung cancer among patients with chronic obstructive pulmonary disease. Ann Am Thorac Soc. 2022;19(4):640–648. doi:10.1513/AnnalsATS.202010-1240OC
   PubMed Web of Science ®Google Scholar
• Nishi MP, Mancuzo EV, Sulmonett N, et al. Pulmonary functional assessment: longitudinal study after treatment of pulmonary tuberculosis. Rev Inst Med Trop Sao Paulo. 2021;63(63):e65. doi:10.1590/s1678-9946202163065
   Web of Science ®Google Scholar
• Tiberi S, Zumla A, Migliori GB. Multidrug and extensively drug-resistant tuberculosis: epidemiology, clinical features, management and treatment. Infect Dis Clin North Am. 2019;33(4):1063–1085. doi:10.1016/j.idc.2019.09.002
   PubMed Web of Science ®Google Scholar
• Shadrach BJ, Kumar S, Deokar K, et al. A study of multidrug resistant tuberculosis among symptomatic household contacts of MDR-TB patients. Indian J Tuberc. 2021;68(1):25–31. doi:10.1016/j.ijtb.2020.09.030
   PubMedGoogle Scholar
• Li F. Clinical characteristics of pulmonary tuberculosis complicated with chronic obstructive pulmonary disease and drug resistance of anti-tuberculosis drugs. Chin J Clin Rational Drug Use. 2019;12(1):68–69.
   Google Scholar
• Tan W. Clinical characteristics of tuberculosis patients with chronic obstructive pulmonary disease and analysis of antituberculosis drug resistance. Syst Med. 2020;5(2):53–55.
   Google Scholar
• Shimeles E, Enquselassie F, Aseffa A, et al. Risk factors for tuberculosis: a case-control study in Addis Ababa, Ethiopia. PLoS One. 2019;14(4):e0214235. doi:10.1371/journal.pone.0214235
   Web of Science ®Google Scholar
• Chu AL, Lecca LW, Calderón RI, et al. Smoking cessation in tuberculosis patients and the risk of tuberculosis infection in child household contacts. Clin Infect Dis. 2021;73(8):1500–1506. doi:10.1093/cid/ciab504
   Web of Science ®Google Scholar
• Tellez-Navarrete NA, Ramon-Luing LA, Muñoz-Torrico M, et al. Malnutrition and tuberculosis: the gap between basic research and clinical trials. J Infect Dev Ctries. 2021;15(3):310–319. doi:10.3855/jidc.12821
   Web of Science ®Google Scholar
• World Health Organization. Global Tuberculosis Report 2021. Geneva: World Health Organization; 2021.
   Google Scholar
• O’Toole RF, Shukla SD, Walters EH. TB meets COPD: an emerging global co-morbidity in human lung disease. Tuberculosis. 2015;95(6):659–663. doi:10.1016/j.tube.2015.08.005
   PubMed Web of Science ®Google Scholar
• Liu FP, Zhang CJ, Wang Y, et al. Multidrug-resistant tuberculosis drug resistance analysis and adverse reactions. Hebei Med J. 2015;37(15):2366–2368.
   Google Scholar
• Rodriguez-Takeuchi SY, Renjifo ME, Medina FJ. Extrapulmonary tuberculosis: pathophysiology and imaging findings. Radiographics. 2019;39(7):2023–2037. doi:10.1148/rg.2019190109
   PubMed Web of Science ®Google Scholar